Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
종목 코드 TNXP
회사 이름Tonix Pharmaceuticals Holding Corp
상장일Mar 29, 2010
CEOLederman (Seth)
직원 수81
유형Ordinary Share
회계 연도 종료Mar 29
주소26 Main Street, Suite 101
도시CHATHAM
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호07928
전화12129809155
웹사이트https://www.tonixpharma.com/
종목 코드 TNXP
상장일Mar 29, 2010
CEOLederman (Seth)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음